Stockreport

Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 [Seeking Alpha]

Arcus Biosciences, Inc.  (RCUS) 
Last arcus biosciences, inc. earnings: 3/5 04:10 pm Check Earnings Report
PDF Instead, they'll focus now on Casdatifan (AB521), which is a wholly owned oral HIF-2a inhibitor. In my view, this makes Casdatifan the core bull thesis, especially wi [Read more]